Phibro Animal Health (NASDAQ:PAHC) Rating Lowered to Buy at StockNews.com

Phibro Animal Health (NASDAQ:PAHC) was downgraded by equities researchers at StockNews.com from a “strong-buy” rating to a “buy” rating in a report issued on Wednesday.

Other equities research analysts have also issued reports about the company. Bank of America upped their price objective on Phibro Animal Health from $13.00 to $15.00 and gave the stock an “underperform” rating in a research note on Friday, August 30th. Barclays lifted their price target on shares of Phibro Animal Health from $13.00 to $20.00 and gave the company an “underweight” rating in a research note on Tuesday, November 12th. Finally, JPMorgan Chase & Co. initiated coverage on shares of Phibro Animal Health in a research note on Tuesday, September 10th. They issued a “neutral” rating and a $22.00 price objective for the company. Three analysts have rated the stock with a sell rating, one has issued a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, Phibro Animal Health has a consensus rating of “Hold” and a consensus price target of $16.50.

Phibro Animal Health Stock Performance

Phibro Animal Health stock opened at $23.75 on Wednesday. The stock’s 50 day simple moving average is $22.96 and its two-hundred day simple moving average is $19.84. The company has a debt-to-equity ratio of 1.81, a quick ratio of 1.69 and a current ratio of 3.23. The stock has a market cap of $961.88 million, a price-to-earnings ratio of 55.23, a PEG ratio of 0.64 and a beta of 0.51. Phibro Animal Health has a fifty-two week low of $9.49 and a fifty-two week high of $25.98.

Phibro Animal Health (NASDAQ:PAHC) last issued its quarterly earnings results on Wednesday, August 28th. The company reported $0.41 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.07. Phibro Animal Health had a return on equity of 21.59% and a net margin of 1.67%. The firm had revenue of $273.16 million for the quarter, compared to analysts’ expectations of $262.44 million. As a group, analysts expect that Phibro Animal Health will post 1.59 earnings per share for the current fiscal year.

Insider Activity at Phibro Animal Health

In other news, Director E Thomas Corcoran acquired 5,000 shares of the firm’s stock in a transaction on Wednesday, September 4th. The stock was acquired at an average price of $20.02 per share, for a total transaction of $100,100.00. Following the completion of the transaction, the director now owns 25,000 shares in the company, valued at approximately $500,500. The trade was a 25.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 50.07% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. CWM LLC raised its position in shares of Phibro Animal Health by 89.8% during the 2nd quarter. CWM LLC now owns 2,188 shares of the company’s stock worth $37,000 after purchasing an additional 1,035 shares during the last quarter. Quantbot Technologies LP purchased a new stake in Phibro Animal Health during the 3rd quarter valued at about $70,000. nVerses Capital LLC purchased a new stake in Phibro Animal Health during the 3rd quarter valued at about $70,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Phibro Animal Health by 63.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,912 shares of the company’s stock valued at $88,000 after buying an additional 1,522 shares during the period. Finally, Summit Securities Group LLC purchased a new stake in shares of Phibro Animal Health in the 2nd quarter valued at approximately $83,000. Institutional investors and hedge funds own 99.34% of the company’s stock.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.